[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609145":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":27,"responsibleParty":44,"collaborators":19,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":19,"overallStatus":66,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"12 Gy in 6 fractions of external beam radiation therapy","EXPERIMENTAL","12 Gy in 6 fractions of conventional external beam radiation therapy using standard-of-care radiation volumes for low-grade orbital lymphoma",[13],"Radiation: External Beam Radiation Therapy",[15],{"type":16,"name":17,"description":9,"armGroupLabels":18,"otherNames":19},"RADIATION","External Beam Radiation Therapy",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Sandy Chang","CONTACT","604-675-4100","202199","sandy.chang@bccancer.bc.ca",[28],{"facility":29,"status":19,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"BC Cancer Vancouver","Vancouver","British Columbia","V5Z4E6","Canada","CA",{"type":36,"coordinates":37},"Point",[38,39],-123.11934,49.24966,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":43,"phoneExt":25,"email":26},"6048776000",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Matthew Chan","Principal Investigator (Co-PI)","100609145","radiotherapy-12gy-in-6-fractions-for-orbital-lymphoma-100609145",false,"NCT07210749","Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma","A Phase II Trial Assessing 12 Gy in 6 Fractions Radiotherapy for Low-Grade B-cell Orbital Lymphoma","Inclusion Criteria:\n\n* Age ≥18 years with stage I-IV indolent NHL\\*\n* Able to provide informed consent\n* Histologically confirmed indolent NHL involving one or both orbits. If bilateral, biopsy of only one orbit is permitted as long as high clinical suspicion of contralateral orbit involvement\n* Measurable orbital disease after biopsy, either clinically or radiographically\n* ECOG performance status 0-3\n* Life expectancy \\>12 months\n* Available for treatment and follow-up (including scheduled post-treatment imaging and ophthalmologic exam)\n* Able and willing to complete quality of life questionnaires via paper or online portal if they provide their email address on the informed consent document\n\n  * Stage II-IV allowed but if systemic therapy given after RT the timing will be recorded, and subjects will be stratified according to receipt of systemic therapy\n\nExclusion Criteria:\n\n* Aggressive NHL histology (including grade 3B follicular lymphoma)\n* Prior RT to orbit\n* Patients requiring treatments outside standard clinical hours\n* Systemic therapy for lymphoma is not permitted within the period of time between 2 weeks prior to RT start and 2 weeks after RT completion\n* Patients who are pregnant\n* History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death and\u002For treated with expected curative outcome (for example, appropriately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, localized prostate cancer, breast ductal carcinoma in-situ, or stage I endometrial cancer)\n* Any medical condition that, in the investigator's judgement, would preclude the individual's safe participation in and completion of the study, or could affect interpretation of the results (e.g. pre-existing retinopathy, active connective tissue disease)\n* Inability to comply with study and follow-up procedures","ALL","18 Years",{"count":58,"type":59},36,"ESTIMATED","INTERVENTIONAL",[62],"NA","Current standard RT doses (24-25Gy) provide excellent disease control for patients with indolent B-cell orbital lymphoma, but can cause significant late toxicities. Ultra-low dose RT (4Gy in 2 fractions) has minimal toxicity but lower disease control, requiring intensive follow-up to salvage persistent tumors. Some centers are moving towards this dose as the new standard. A recent study using 12Gy in 4 fractions to any body site showed early data suggesting high disease control rates with minimal toxicity. This study assesses 12Gy in 6 fractions, aiming to enhance disease control over 4Gy while reducing toxicity compared to 24Gy.",[65],"Orbital Lymphoma","NOT_YET_RECRUITING","2025-10-02",{"date":69,"type":70},"2025-10-07","ACTUAL",{"date":72,"type":59},"2025-11-01",{"date":74,"type":59},"2036-08-31",{"name":5,"class":6},1]